Business Description
StemCell Institute
ISIN : JP3399640006
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 323.95 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.63 | |||||
Beneish M-Score | -1.78 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.7 | |||||
3-Year EBITDA Growth Rate | 61.9 | |||||
3-Year EPS without NRI Growth Rate | 64.3 | |||||
3-Year Book Growth Rate | 26.8 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.55 | |||||
9-Day RSI | 51.47 | |||||
14-Day RSI | 50.73 | |||||
6-1 Month Momentum % | -12.24 | |||||
12-1 Month Momentum % | -38.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.2 | |||||
Quick Ratio | 1.19 | |||||
Cash Ratio | 0.76 | |||||
Days Inventory | 15.1 | |||||
Days Sales Outstanding | 205.9 | |||||
Days Payable | 12.64 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.02 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.51 | |||||
Operating Margin % | 16.68 | |||||
Net Margin % | 12.53 | |||||
FCF Margin % | 5.36 | |||||
ROE % | 12.49 | |||||
ROA % | 5.07 | |||||
ROIC % | 5.83 | |||||
3-Year ROIIC % | 10.09 | |||||
ROC (Joel Greenblatt) % | 61.34 | |||||
ROCE % | 16.07 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 53.65 | |||||
PE Ratio without NRI | 56.53 | |||||
Price-to-Owner-Earnings | 82.92 | |||||
PEG Ratio | 4.01 | |||||
PS Ratio | 6.72 | |||||
PB Ratio | 6.19 | |||||
Price-to-Tangible-Book | 6.29 | |||||
Price-to-Free-Cash-Flow | 125.46 | |||||
Price-to-Operating-Cash-Flow | 49.85 | |||||
EV-to-EBIT | 33.45 | |||||
EV-to-EBITDA | 33.45 | |||||
EV-to-Revenue | 5.58 | |||||
EV-to-FCF | 104.5 | |||||
Price-to-Peter-Lynch-Fair-Value | 4.03 | |||||
Price-to-Graham-Number | 3.98 | |||||
Price-to-Net-Current-Asset-Value | 25.1 | |||||
Earnings Yield (Greenblatt) % | 2.99 | |||||
FCF Yield % | 0.8 | |||||
Forward Rate of Return (Yacktman) % | 15.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
StemCell Institute Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | 2,481.193 | ||
EPS (TTM) (円) | 30.345 | ||
Beta | 1.75 | ||
Volatility % | 28.35 | ||
14-Day RSI | 50.73 | ||
14-Day ATR (円) | 48.236279 | ||
20-Day SMA (円) | 1637.5 | ||
12-1 Month Momentum % | -38.02 | ||
52-Week Range (円) | 1213 - 2658 | ||
Shares Outstanding (Mil) | 10.25 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
StemCell Institute Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
StemCell Institute Stock Events
Event | Date | Price(円) | ||
---|---|---|---|---|
No Event Data |
StemCell Institute Frequently Asked Questions
What is StemCell Institute(TSE:7096)'s stock price today?
When is next earnings date of StemCell Institute(TSE:7096)?
Does StemCell Institute(TSE:7096) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |